Kimberly-Clark is making a big move with a nearly $50 billion deal. The North Texas company plans to acquire Kenvue Inc., a personal care product provider with brands like Tylenol, in a deal that ...

Barclays raised the firm’s price target on Kenvue (KVUE) to $18 from $17 and keeps an Equal Weight rating on the shares following the Q3 report. The company’s sales came in below expectations, with ...

David Paul Morris / Bloomberg Irving-based Kimberly-Clark announced a blockbuster deal Monday morning to acquire consumer health care company Kenvue for nearly $50 billion. Kimberly-Clark, one of the ...

Kenvue offers stable financials, a robust 5% dividend yield, and the stock trades at a significant discount to peers and historical averages. KVUE's recent decline, driven by Tylenol-related headlines ...

(AP) - Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about ...